Revenue - License and Collaboration Agreements- Narrative (Details)				1 Months Ended	12 Months Ended
	May 28, 2021 USD ($)	Aug. 03, 2020 USD ($) shares	Jan. 07, 2018 USD ($)	Oct. 31, 2014	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Expenses related to collaboration agreement					$ 531,627,000	$ 508,594,000	$ 299,349,000
Income tax expense					508,000	3,299,000	0
Unrealized gain (loss) on investments					$ (3,224,000)	(691,000)	(130,000)
Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]					Other Nonoperating Income (Expense)
Milestone Payments
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Expenses related to collaboration agreement						5,000,000
BeiGene Agreement
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Up-front fee received			$ 10,000,000
Revenue from performance obligation expected to be earned			$ 123,000,000
Termination of contract, period after first commercial sale of product			10 years
Period required for notice of termination of contract			60 days
Revenue from performance obligation earned							500,000
Revenue					$ 0	0	0
Contract with Customer, Milestone Payments Receivable					0
BeiGene Agreement | Maximum
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Collaborative Arrangement, Research and Development Arrangement, Discovery and Collaboration Agreement, Royalty Percentage			0.20
BeiGene Agreement | Licenses of Intellectual Property
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue from performance obligation earned								$ 9,500,000
Contract with Customer, Milestone Payments Receivable						5,000,000
BeiGene Agreement | Manufacturing Supply Services
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue from performance obligation earned							200,000
Revenue recognized							(2,000,000)
Cost sharing receivable					0	300,000
Revenue from Contract with Customer, Including Assessed Tax					0	400,000
Contract with Customer, Liability, Revenue Recognized							1,800,000
BeiGene Agreement | Milestone Payments
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue recognized						0	0
Pfizer Agreement
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Termination of contract, period after first commercial sale of product				10 years
Period required for notice of termination of contract				60 days
Expenses related to collaboration agreement							4,800,000
Pfizer Agreement | Research and Development Services
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Expenses related to collaboration agreement							$ 1,500,000
ORIC Pharmaceuticals Agreement
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Stock received as part of stock issuance and license agreements (shares) | shares		588,235
License agreement, period of transfer restrictions		18 months
License agreement, period of agreement after first commercial sale		10 years
ORIC Pharmaceuticals Agreement | Level 3
Research and Development Arrangement, Contract to Perform for Others [Line Items]
License agreement, transaction price		$ 11,400,000
Zai Collaboration and License Agreement
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Collaboration Arrangement, Research and Development Arrangement, Up-Front Fee Received	$ 65,000,000
Collaborative Arrangement, Research and Development Arrangement, Discovery and Collaboration Agreement, Termination of Contract, Period after First Commercial Sale of Product	10 years
Collaboration Arrangement, Research and Development Arrangement, Contract to Perform for Others, Period Required for Notice of Termination of Contract	12 months
Collaboration Arrangement, Research and Development Arrangement, Transaction Price	$ 66,600,000
Contract with Customer, Milestone Payments Receivable					5,000,000	0
Zai Collaboration and License Agreement | Licenses of Intellectual Property
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue from Contract with Customer, Including Assessed Tax						66,600,000
Income tax expense						3,300,000
Zai Collaboration and License Agreement | Manufacturing Supply Services
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue from Contract with Customer, Including Assessed Tax					1,500,000	0
Zai Collaboration and License Agreement | Milestone Payments | adagrasib
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Income tax expense					500,000
Zai Collaboration and License Agreement | Sales Milestone Payments
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Collaboration Arrangement, Research and Development Arrangement, Contract to Perform for Others, Compensation Expected to be Earned	180,000,000
Zai Collaboration and License Agreement | Royalties
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue					$ 0	$ 0
Zai Collaboration and License Agreement | Development and Regulatory-Based Milestone Payments
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Collaboration Arrangement, Research and Development Arrangement, Contract to Perform for Others, Compensation Expected to be Earned	$ 93,000,000